Evidence map›Paper›PMID 33688686›Full record

ArticlemedRxiv : the preprint server for health sciences2021

IL-13 is a driver of COVID-19 severity.

Alexandra N Donlan, Tara E Sutherland, Chelsea Marie, Saskia Preissner, Ben T Bradley, Rebecca M Carpenter, Jeffrey M Sturek, Jennie Z Ma, G Brett Moreau, Jeffrey R Donowitz and 17 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 72 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 5 institutions in 3 countries.

Alexandra N DonlanDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville VA 22908 USA.
Tara E SutherlandLydia Becker Institute of Immunology and Inflammation, School of Biological Sciences, University of Manchester, Manchester Academic Health Sciences Centre, Manchester M13 9PL, United Kingdom.
Chelsea MarieDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville VA 22908 USA.
Saskia PreissnerDepartment Oral and Maxillofacial Surgery, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353 Berlin, Germany.
Ben T BradleyDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle WA 98109 USA.
Rebecca M CarpenterDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville VA 22908 USA.
Jeffrey M SturekDivision of Pulmonary and Critical Care Medicine, Department of Medicine, University of Virginia School of Medicine, Charlottesville VA 22908 USA.
Jennie Z MaDepartment of Public Health Sciences, University of Virginia School of Medicine, Charlottesville VA 22908 USA.
G Brett MoreauDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville VA 22908 USA.
Jeffrey R DonowitzDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville VA 22908 USA.
Gregory A BuckDepartment of Microbiology and Immunology, School of Medicine, Virginia Commonwealth University, Richmond VA 23298 USA.
Myrna G SerranoDepartment of Microbiology and Immunology, School of Medicine, Virginia Commonwealth University, Richmond VA 23298 USA.
Stacey L BurgessDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville VA 22908 USA.
Mayuresh M AbhyankarDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville VA 22908 USA.
Cameron MuraSchool of Data Science and Department of Biomedical Engineering University of Virginia, Charlottesville, VA 22904.
Philip E BourneSchool of Data Science and Department of Biomedical Engineering University of Virginia, Charlottesville, VA 22904.
Robert PreissnerScience-IT and Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Philippstrasse 12, 10115 Berlin, Germany.
Mary K YoungDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville VA 22908 USA.
Genevieve R LyonsDepartment of Public Health Sciences, University of Virginia School of Medicine, Charlottesville VA 22908 USA.
Johanna J LoombaIntegrated Translational Health Research Institute (iTHRIV), University of Virginia School of Medicine, Charlottesville VA 22908 USA.
Sarah J RatcliffeDepartment of Public Health Sciences, University of Virginia School of Medicine, Charlottesville VA 22908 USA.
Melinda D PoulterDepartment of Pathology University of Virginia School of Medicine, Charlottesville VA 22908 USA.
Amy J MathersDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville VA 22908 USA.
Anthony DayLydia Becker Institute of Immunology and Inflammation, School of Biological Sciences, University of Manchester, Manchester Academic Health Sciences Centre, Manchester M13 9PL, United Kingdom.
Barbara J MannDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville VA 22908 USA.
Judith E AllenLydia Becker Institute of Immunology and Inflammation, School of Biological Sciences, University of Manchester, Manchester Academic Health Sciences Centre, Manchester M13 9PL, United Kingdom.
William A PetriDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville VA 22908 USA.
University of Virginia · USManchester Academic Health Science Centre · GBVirginia Commonwealth University · USHumboldt-Universität zu Berlin · DEUniversity of Washington · US

Funding

CD2H - The National COVID Cohort Collaborative (N3C) IDeA CTR CollaborationU24TR002306 · NCATS · UNIVERSITY OF COLORADO DENVER · PI CHUTE, CHRISTOPHER G, EICHMANN, DAVID A. · 2017 to 2021
$28.9M
The integrated Translational Health Research Institute of Virginia (iTHRIV): Using Data to Improve HealthUL1TR003015 · NCATS · UNIVERSITY OF VIRGINIA · PI BROWN, DONALD E, JOHNSTON, KAREN C. · 2019 to 2023
$20.3M
Role of Type 2 Immunity in Innate Protection from C. difficileR01AI124214 · NIAID · UNIVERSITY OF VIRGINIA · PI William A Petri · 2016 to 2026
$5.4M
Institutional Career Development CoreKL2TR003016 · NCATS · UNIVERSITY OF VIRGINIA · PI PAPIN, JASON, WORRALL, BRADFORD B · 2019 to 2023
$3.9M
Role of Host Protein Kinase C in CryptosporidiosisR01AI148518 · NIAID · UNIVERSITY OF VIRGINIA · PI MARIE, CHELSEA S. · 2020 to 2024
$3.3M
Gut microbiome communication with the bone marrow regulates intestinal inflammation.R01AI146257 · NIAID · UNIVERSITY OF VIRGINIA · PI BURGESS, STACEY L · 2020 to 2025
$2.0M
Interdisciplinary Training in Systems & Biomolecular Data ScienceT32GM145443 · NIGMS · UNIVERSITY OF VIRGINIA · PI Kevin A Janes, Jason Papin · 2022 to 2026
$1.5M
Medical Research Council MR/K01207X/2NCATS NIH HHS KL2 TR003016NCATS NIH HHS U24 TR002306NCATS NIH HHS UL1 TR003015NIAID NIH HHS R01 AI124214NIAID NIH HHS R01 AI146257NIAID NIH HHS R01 AI148518NIGMS NIH HHS T32 GM145443Wellcome Trust
6 · The paper itself

Abstract

Immune dysregulation is characteristic of the more severe stages of SARS-CoV-2 infection. Understanding the mechanisms by which the immune system contributes to COVID-19 severity may open new avenues to treatment. Here we report that elevated interleukin-13 (IL-13) was associated with the need for mechanical ventilation in two independent patient cohorts. In addition, patients who acquired COVID-19 while prescribed Dupilumab had less severe disease. In SARS-CoV-2 infected mice, IL-13 neutralization reduced death and disease severity without affecting viral load, demonstrating an immunopathogenic role for this cytokine. Following anti-IL-13 treatment in infected mice, in the lung, hyaluronan synthase 1 (

Identifiers

PMID33688686
PMCPMC7941663
OpenAlexW3036130366

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.